A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

Guanylyl cyclase C (GCC) is a cell-surface protein that is expressed by normal intestinal epithelial cells, more than 95% of metastatic colorectal cancers (mCRC), and the majority of gastric and pancreatic cancers. Due to strict apical localization, systemically delivered GCC-targeting agents should not reach GCC in normal intestinal tissue, while accessing antigen in tumor. We generated an investigational antibody-drug conjugate (TAK-264, formerly MLN0264) comprising a fully human anti-GCC monoclonal antibody conjugated to monomethyl auristatin E via a protease-cleavable peptide linker. TAK-264 specifically bound, was internalized by, and killed GCC-expressing cells in vitro in an antigen-density-dependent manner. In GCC-expressing xenograft models with similar GCC expression levels/patterns observed in human mCRC samples, TAK-264 induced cell death, leading to tumor regressions and long-term tumor growth inhibition. TAK-264 antitumor activity was generally antigen-density-dependent, although some GCC-expressing tumors were refractory to TAK-264-targeted high local concentrations of payload. These data support further evaluation of TAK-264 in the treatment of GCC-expressing tumors.

[1]  D. Ryan,et al.  Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies , 2016, Clinical Cancer Research.

[2]  A. Seicean,et al.  New targeted therapies in pancreatic cancer. , 2015, World journal of gastroenterology.

[3]  Suzanne F. Jones,et al.  Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. , 2014, Journal of Clinical Oncology.

[4]  P. Sapra,et al.  The next generation of antibody drug conjugates. , 2014, Seminars in oncology.

[5]  R. Pazdur,et al.  U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma , 2012, Clinical Cancer Research.

[6]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Brunetti,et al.  Mice anesthesia, analgesia, and care, Part I: anesthetic considerations in preclinical research. , 2012, ILAR journal.

[8]  M. Sliwkowski,et al.  Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer , 2011, Clinical Cancer Research.

[9]  B. Teicher,et al.  Antibody Conjugate Therapeutics: Challenges and Potential , 2011, Clinical Cancer Research.

[10]  Hailing Yang,et al.  Mitotic Centromere-associated Kinesin (MCAK) Mediates Paclitaxel Resistance* , 2011, The Journal of Biological Chemistry.

[11]  Serdar Öztuzcu,et al.  Peripheral blood guanylyl cyclase c (GCC) expressions are associated with prognostic parameters and response to therapy in colorectal cancer patients , 2011, Tumor Biology.

[12]  Heidi Ledford Toxic antibodies blitz tumours , 2011, Nature.

[13]  R. Goldberg,et al.  TREATMENT OF METASTATIC COLORECTAL CANCER Review of recent advances , 2005 .

[14]  D. Sargent,et al.  Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis , 2011, Annals of Surgical Oncology.

[15]  F. Coppedè,et al.  Genetics, Cytogenetics, and Epigenetics of Colorectal Cancer , 2011, Journal of biomedicine & biotechnology.

[16]  Yanfang Guan,et al.  Loss of Guanylyl Cyclase C (GCC) Signaling Leads to Dysfunctional Intestinal Barrier , 2011, PloS one.

[17]  John P Leonard,et al.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.

[18]  I. Nagtegaal,et al.  Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases , 2010, British Journal of Cancer.

[19]  D. Benjamin,et al.  Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate , 2010, Clinical Cancer Research.

[20]  Zhong Xu,et al.  Ectopic expression of guanylyl cyclase C in gastric cancer as a potential biomarker and therapeutic target , 2009, Journal of digestive diseases.

[21]  S. Waldman,et al.  Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer. , 2009, Biomarkers in medicine.

[22]  S. Waldman,et al.  Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. , 2008, Journal of the National Cancer Institute.

[23]  Guy Cavet,et al.  Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. , 2008, Cancer research.

[24]  H. Friess,et al.  Uroguanylin inhibits proliferation of pancreatic cancer cells , 2008, Scandinavian journal of gastroenterology.

[25]  Terry Hyslop,et al.  A Validated Quantitative Assay to Detect Occult Micrometastases by Reverse Transcriptase-Polymerase Chain Reaction of Guanylyl Cyclase C in Patients with Colorectal Cancer , 2006, Clinical Cancer Research.

[26]  C. Lepage,et al.  Epidemiology and Management of Liver Metastases From Colorectal Cancer , 2006, Annals of surgery.

[27]  G. Launoy,et al.  A population‐based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer , 2006, The British journal of surgery.

[28]  C. Swanton,et al.  Chromosomal Instability, Colorectal Cancer and Taxane Resistance , 2006, Cell cycle.

[29]  S. Waldman,et al.  Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer , 2005, Expert review of molecular diagnostics.

[30]  D. Pezet,et al.  Guanylyl cyclase C as a reliable immunohistochemical marker and its ligand Escherichia coli heat-stable enterotoxin as a potential protein-delivering vehicle for colorectal cancer cells. , 2005, European journal of cancer.

[31]  C. Ko,et al.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.

[32]  C. Milstein,et al.  Pillars Article: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 256 (5517): 495–497. , 2005 .

[33]  A. Wahl,et al.  In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  H. Saya,et al.  Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint , 2004, Cancer Research.

[35]  Takashi Takahashi,et al.  Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. , 2003, The American journal of pathology.

[36]  Damon L. Meyer,et al.  cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.

[37]  Jason Y. Park,et al.  Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[38]  S. Waldman,et al.  In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C--specific ligand. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  L. Forte,et al.  Chemical synthesis of Escherichia coli ST(h) analogues by regioselective disulfide bond formation: biological evaluation of an (111)In-DOTA-Phe(19)-ST(h) analogue for specific targeting of human colon cancers. , 2002, Bioconjugate chemistry.

[40]  M. Kruhøffer,et al.  Guanylin stimulates regulated secretion from human neuroendocrine pancreatic cells. , 1998, Gastroenterology.

[41]  S. Waldman,et al.  Escherichia coli heat-stable enterotoxin receptors , 1996, Diseases of the colon and rectum.

[42]  S. Waldman,et al.  Internalization of E. coli ST mediated by guanylyl cyclase C in T84 human colon carcinoma cells. , 1995, Biochimica et biophysica acta.

[43]  S. Waldman,et al.  Escherichia coli heat-stable toxin receptors in human colonic tumors. , 1994, Gastroenterology.

[44]  G. Schoolnik,et al.  Ligand‐based histochemical localization and capture of cells expressing heat‐stable enterotoxin receptors , 1993, Molecular microbiology.

[45]  Mitchell Cohen,et al.  Binding ofE. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes , 1987, Digestive Diseases and Sciences.

[46]  P. Jönsson,et al.  Natural history of patients with untreated liver metastases from colorectal cancer. , 1981, American journal of surgery.

[47]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[48]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[49]  S. Waldman,et al.  Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas. , 2010, Human pathology.

[50]  A. Venkitaraman,et al.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. , 2003, Cancer cell.

[51]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.